Bayer Cropscience India Limited (BAYERCROP) AI Stock Analysis

• Market Cap: ₹203.17B
• Dividend Yield: 1.57%
• Average Volume (3M): 2.83K
• Price to Earnings (P/E): 53.5
• Beta (1Y): 1.03
• Revenue Growth: 8.92%
• EPS Growth: 5.06%
• Country: IN
• Employees: 1,317
• Sector: Basic Materials
• Sector Strength: 58
• Industry: Agricultural Inputs
• EPS (TTM): 21.30
• Shares Outstanding: 44,942,093
• 10 Day Avg. Volume: 4,614
• 30 Day Avg. Volume: 2,834
• PEG Ratio: -1.63
• Price to Book (P/B): 7.59
• Price to Sales (P/S): 3.95
• P/FCF Ratio: 83.41
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 148.26
• Revenue Forecast (FY): ₹57.12B

• Rating: 61 Neutral
• Price Target: ₹4,747.00 ▲(5.29% Upside)
• Action: Reiterated Date: 11/12/25
• Date: Action: Reiterated 11/12/25

Bayer Cropscience India Limited's overall stock score is primarily influenced by its strong financial performance, characterized by stable revenue growth and a robust balance sheet. However, bearish technical indicators and a relatively high P/E ratio suggest caution. The stock's valuation and technical analysis indicate potential risks, while the absence of earnings call data and corporate events limits additional insights.

Positive Factors

Strong Balance Sheet

A robust balance sheet with low leverage enhances financial stability and flexibility, allowing for strategic investments and resilience against economic fluctuations.

Revenue Growth

Sustained revenue growth indicates strong market demand and effective product positioning, supporting long-term business expansion and competitiveness.

Cash Reserves

Strong cash reserves provide a buffer against economic downturns and enable the company to seize growth opportunities without financial strain.

Negative Factors

Declining Profit Margins

Decreasing profit margins suggest rising costs or pricing pressures, which could impact profitability and require strategic adjustments to maintain competitiveness.

Operating Cash Flow Decrease

A decline in operating cash flow may limit the company's ability to fund operations and invest in growth, necessitating improved cash management strategies.

Net Profit Margin Decline

Falling net profit margins indicate reduced profitability, which could affect future earnings and shareholder returns if not addressed through cost control or revenue enhancement.

Bayer Cropscience India Limited Business Overview & Revenue Model

Company Description

Bayer CropScience Limited engages in the manufacture, sale, and distribution of insecticides, fungicides, herbicides, and various other agrochemical products and corn seeds in India, Germany, Bangladesh, and internationally. It provides medicines primarily in the therapeutic areas of cardiology, gynecology, diabetes, oncology, and ophthalmology; and diagnostic imaging equipment and other contrast agents, including computed tomography, X-Ray, and magnetic resonance imaging devices. In addition, the company offers consumer health products that are used as a daily health solution to treat minor illnesses, as well as sells and distributes hybrid seeds, such as corn and paddy. Further, it provides digital farming products comprising FarmRiseTM and digital prediction systems that integrate data from farm equipment, satellites, field sensors, irrigation systems, drones, and other input sources and then analyze that data to allow farmers to make decisions through data science and predictive analytics. The company also exports its products. Bayer CropScience Limited was incorporated in 1958 and is based in Thane, India.

How the Company Makes Money

Bayer Cropscience India Limited generates revenue primarily through the sale of agricultural chemicals, including crop protection products such as herbicides and insecticides, as well as seeds and biotechnology products. The company's revenue model is based on a combination of direct sales to farmers and distribution through a network of retailers and agricultural cooperatives. Key revenue streams include product sales in both domestic and export markets, with significant contributions from premium products that offer advanced formulations and sustainable solutions. Additionally, BAYERCROP engages in partnerships with research institutions, agricultural organizations, and other stakeholders to enhance product development and market reach, further contributing to its earnings.

Bayer Cropscience India Limited Financial Statement Overview

Summary

Bayer Cropscience India Limited demonstrates a strong financial position with stable revenue growth and a solid balance sheet featuring low leverage and high equity. However, the decrease in profit margins and operating cash flow in 2025 presents a challenge. The company's strong cash reserves and capital structure mitigate risks, but addressing margin pressures is crucial for sustaining future growth.

Income Statement

Bayer Cropscience India Limited has shown consistent revenue growth, with Total Revenue increasing from 2020 to 2025. However, gross profit margin declined significantly from 45.36% in 2024 to 28.14% in 2025, indicating rising cost pressures or pricing issues. Net profit margin also decreased from 14.50% in 2024 to 10.38% in 2025. Despite these declines, the company maintains a solid EBIT margin in 2025 at 11.05% and an EBITDA margin of 14.79%, reflecting efficient operations.

Balance Sheet

The balance sheet of Bayer Cropscience India Limited is robust, with a low debt-to-equity ratio of 0.04 in 2025, indicating minimal leverage risk. The equity ratio is strong at 54.35%, showcasing a healthy capital structure. The company also maintains high levels of cash and equivalents, supporting liquidity and stability. Return on Equity (ROE) decreased slightly to 19.92% in 2025, yet remains impressive.

Cash Flow

Cash flow performance is mixed; operating cash flow decreased from 2024 to 2025, which could impact future investments. However, free cash flow generation is stable, and the free cash flow to net income ratio is robust, indicating good cash conversion. Despite the decline in operating cash flow, the company has maintained strong free cash flow growth in prior years.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	55.73B	54.73B	51.06B	51.40B	47.34B	42.61B
Gross Profit	21.43B	20.59B	21.81B	23.09B	20.57B	17.99B
EBITDA	7.12B	6.43B	9.43B	8.86B	7.90B	7.80B
Net Income	6.09B	5.68B	7.41B	7.58B	6.45B	4.93B
Balance Sheet
Total Assets	51.91B	52.46B	45.97B	46.79B	43.53B	42.39B
Cash, Cash Equivalents and Short-Term Investments	7.16B	9.29B	12.11B	9.02B	8.19B	12.57B
Total Debt	1.02B	1.05B	471.00M	735.00M	864.00M	263.00M
Total Liabilities	20.68B	23.95B	17.48B	19.66B	18.29B	16.89B
Stockholders Equity	31.23B	28.50B	28.49B	27.12B	25.24B	25.50B
Cash Flow
Free Cash Flow	-682.00M	2.59B	9.06B	5.32B	1.60B	6.45B
Operating Cash Flow	-349.00M	3.00B	9.52B	6.09B	2.15B	6.87B
Investing Cash Flow	-90.00M	389.00M	4.00M	833.00M	642.00M	67.00M
Financing Cash Flow	-1.84B	-6.10B	-6.56B	-6.13B	-7.03B	-5.56B

Bayer Cropscience India Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 4508.60
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:BAYERCROP, the sentiment is Negative. The current price of 4508.6 is below the 20-day moving average (MA) of 4652.07, below the 50-day MA of 4551.29, and below the 200-day MA of 5027.54, indicating a bearish trend. The MACD of -19.21 indicates Positive momentum. The RSI at 44.63 is Neutral, neither overbought nor oversold. The STOCH value of 29.25 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:BAYERCROP.

Bayer Cropscience India Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
COROMANDEL	74 Outperform	₹578.32B	33.00	―	0.50%	32.88%	75.74%
PIIND	74 Outperform	₹438.44B	39.45	―	0.49%	-5.90%	-14.80%
UPL	68 Neutral	₹513.80B	42.42	―	0.77%	8.14%	―
CHAMBLFERT	62 Neutral	₹165.34B	8.23	―	2.13%	19.70%	22.23%
Sector *	61 Neutral	$10.43B	7.12	-0.05%	2.87%	2.86%	-36.73%
SUMICHEM	61 Neutral	₹192.60B	77.71	―	0.26%	8.69%	12.26%
BAYERCROP	61 Neutral	₹203.17B	53.52	―	1.57%	8.92%	5.06%